Monthly Archives: November 2023

FDA’s OPDP Issues Two New Untitled Letters

While enforcement has been at a low ebb for quite some time with FDA’s Office of Prescription Drug Promotion (OPDP), this week took a different turn with the posting of two new untitled letters sent October 31. That brings the … Continue reading

Posted in OPDP, Regulatory Communications | Tagged , , | Comments Off on FDA’s OPDP Issues Two New Untitled Letters